CAS 1802929-43-6

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-[4-(1-oxo-2-propen-1-yl)-1-piperazinyl]propyl]pyrido[2,3-d]pyrimidin-7(8H)-one

CAS : 1802929-43-6

Formule : C₂₆H₃₀Cl₂N₆O₄

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 561.4602

Ref: IN-DA01DH0S

PRN1371

CAS : 1802929-43-6

PRN1371

Degré de pureté : ≥98%

Masse moléculaire : 561.46g/mol

Ref: 54-BUP04899

PRN1371

CAS : 1802929-43-6

PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).

Formule : C₂₆H₃₀Cl₂N₆O₄

Degré de pureté : 98.65%

Couleur et forme : Solid

Masse moléculaire : 561.46

Ref: TM-TQ0015

PRN1371

CAS : 1802929-43-6

PRN1371 is a novel, small molecule compound that inhibits the activity of cyclin-dependent kinases 4 and 6 (CDK4/6). It is a selective inhibitor of CDK4/6 that has been shown to inhibit tumor growth and metastasis in experimental models. PRN1371 has demonstrated an ability to inhibit tumor growth by targeting the CDK4/6 pathway, which is important for cell cycle progression. This agent also interacts with hydrogen bonds, which may contribute to its selectivity. PRN1371 binds to the protein target with high affinity and specificity.
PRN1371 is currently being studied in phase II clinical trials for pediatric patients with bladder cancer.

Formule : C₂₆H₃₀Cl₂N₆O₄

Degré de pureté : Min. 98 Area-%

Couleur et forme : Powder

Masse moléculaire : 561.46 g/mol

Ref: 3D-BP179867